Prevalence and determinants of selected cardio-metabolic risk factors among people living with HIV/AIDS and receiving care in the South West Regional Hospitals of Cameroon: a cross-sectional study

Roland Cheofor Ngu, Simeon-Pierre Choukem, Christian Akem Dimala, Julius N Ngu, Gottlieb Lobe Monekosso, Roland Cheofor Ngu, Simeon-Pierre Choukem, Christian Akem Dimala, Julius N Ngu, Gottlieb Lobe Monekosso

Abstract

Objective: Metabolic disorders and cardiovascular risk factors are not routinely assessed in the care of HIV patients in developing countries, known to have the highest disease burden. We described the prevalence and factors associated with major cardio-metabolic risk factors (obesity, diabetes and hypertension) in HIV/AIDS patients.

Results: The prevalence of diabetes, hypertension and obesity were 11.3% (95% CI 8.10-15.43), 24.8% (95% CI 20.1-30.0) and 14.5% (95% CI 11.1-19.3) respectively. Central obesity and high alcohol intake were the factors significantly associated with diabetes mellitus, while central obesity and overweight/obesity were significantly associated with having hypertension. Short duration of antiretroviral therapy was the significant predisposing factor for obesity. On multivariate analyses, the only association observed was between central obesity and diabetes (Adjusted OR 2.52, 95% CI 1.01-6.30, P = 0.048). Conclusively, DM, HTN and obesity are highly prevalent in HIV/AIDS patients in the SWR hospitals of Cameroon, with that of DM and obesity being higher than that seen in the general population while that of HTN equaling that of the general population. Awareness of these data among clinicians involved in the management of these patients should be emphasized.

Keywords: Cameroon; Diabetes; HIV/AIDS; Hypertension; Obesity.

References

    1. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132–137. doi: 10.2337/diacare.28.1.132.
    1. Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008;48:272–280. doi: 10.1097/QAI.0b013e31817af461.
    1. IDF Worldwide Definition of the Metabolic Syndrome [Internet]. [cited 2014 Mar 18]. .
    1. Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, et al. Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Lipids Health Dis. 2013;12:50. doi: 10.1186/1476-511X-12-50.
    1. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375–1383. doi: 10.1097/01.aids.0000181011.62385.91.
    1. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666–E1673. doi: 10.1152/ajpendo.00550.2006.
    1. Boyer S, Koulla-Shiro S, Abé C, Spire B, Moatti J-P. Implementing operational research to scale-up access to antiretroviral therapy for HIV infection: lessons learned from the Cameroonian experience. Curr Opin HIV AIDS. 2011;6:239–244. doi: 10.1097/COH.0b013e3283478757.
    1. Dean A, Sullivan K, Soe M. OpeOpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. [Internet]. 2013 [cited 2018 Feb 5]. .
    1. Malaza A, Mossong J, Bärnighausen T, Newell M-L. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS ONE. 2012;7:e47761. doi: 10.1371/journal.pone.0047761.
    1. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005;28:132–137. doi: 10.2337/diacare.28.1.132.
    1. Shen Y, Wang Z, Liu L, Zhang R, Zheng Y, Lu H. Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China. BMC Infect Dis. 2013;13:79. doi: 10.1186/1471-2334-13-79.
    1. Standards of Medical Care in Diabetes—2011. Diabetes Care. 2011;34:S11–S61. doi: 10.2337/dc11-S011.
    1. Verdecchia P, Angeli F, Verdecchia P, Angeli F. The Seventh Report of the Joint National Committee on the prevention, detection, evaluation and treatment of high blood pressure: the weapons are ready. Rev Esp Cardiol. 2003;56:843–847. doi: 10.1016/S0300-8932(03)76970-X.
    1. WHO: Global database on body mass index [Internet]. [cited 2017 Feb 11]. .
    1. Topiwala A, Allan CL, Valkanova V, Zsoldos E, Filippini N, Sexton C, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017;357:j2353. doi: 10.1136/bmj.j2353.
    1. IDF type 2 diabetes management guidelines lifestyle diet exercise|NDEI [Internet]. [cited 2018 Feb 5]. .
    1. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17. doi: 10.1186/1751-0473-3-17.
    1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149. doi: 10.1016/j.diabres.2013.11.002.
    1. Araujo S, Bañón S, Machuca I, Moreno A, Pérez-Elías MJ, Casado JL. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs. Eur J Endocrinol. 2014;171:545–554. doi: 10.1530/EJE-14-0337.
    1. Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am. 2014;43:685–696. doi: 10.1016/j.ecl.2014.05.003.
    1. Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin North Am. 2014;28:457–476. doi: 10.1016/j.idc.2014.05.003.
    1. Bogner JR, Vielhauer V, Beckmann RA, Michl G, Wille L, Salzberger B, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237–244. doi: 10.1097/00042560-200107010-00004.
    1. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598. doi: 10.1016/S0140-6736(00)04056-3.
    1. Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443–449. doi: 10.1097/00126334-200108150-00004.
    1. van der Valk M, Gisolf EH, Reiss P, Wit FW, Japour A, Weverling GJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847–855. doi: 10.1097/00002030-200105040-00005.
    1. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512. doi: 10.1210/jc.2006-2190.
    1. Diouf A, Cournil A, Ba-Fall K, Ngom-Guèye NF, Eymard-Duvernay S, Ndiaye I, et al. Diabetes and hypertension among patients receiving antiretroviral treatment since 1998 in Senegal: prevalence and associated factors. ISRN AIDS. 2012;2012:621565. doi: 10.5402/2012/621565.
    1. Kamadjeu RM, Edwards R, Atanga JS, Kiawi EC, Unwin N, Mbanya J-C. Anthropometry measures and prevalence of obesity in the urban adult population of Cameroon: an update from the Cameroon Burden of Diabetes Baseline Survey. BMC Public Health. 2006;6:228. doi: 10.1186/1471-2458-6-228.
    1. Aoun S, Ramos E. Hypertension in the HIV-infected patient. Curr Sci. 2000;2:478–481. doi: 10.1007/s11906-000-0031-1.
    1. Ekali LG, Johnstone LK, Echouffo-Tcheugui JB, Kouanfack C, Dehayem MY, Fezeu L, et al. Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment. Diabetes Metab. 2013;39:71–77. doi: 10.1016/j.diabet.2012.08.012.
    1. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens. 2003;21:1377–1382. doi: 10.1097/00004872-200307000-00028.
    1. Cameroon Obesity—adult prevalence rate—Demographics [Internet]. [cited 2017 Mar 4]. .
    1. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557–561.
    1. Muhammad S, Sani MU, Okeahialam BN. Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Niger Med J. 2013;54:185–190. doi: 10.4103/0300-1652.114591.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever